Derry suffer third successive Christy Ring Final defeat
Derry suffered a third successive Christy Ring Cup Final defeat as they were beaten 1-27 to 1-24 by London at Croke Park.
The Oak Leafers lost their previous two deciders against Kildare and Meath, and this year's three-point loss means their painful wait for a first Christy Ring Cup goes on.
Advertisement
London's narrow victory helped them to end their 13-year wait to lift the trophy and promotion to the Joe McDonagh Cup next year.
The two sides had traded five points each before David Devine fired home a goal for London on 11 minutes.
Derry responded through Thomas Brady's fantastic long-range strike which drew them level once again.
London kept tagging on points and lead 1-15 to 1-12 at half-time courtesy of a few late points from Devine and Dylan Dawson.
Derry rallied and managed to close the gap by the 51st minute, but Neil Rogers' men re-established their advantage through Conor O'Carroll, Dawson and Jack Morrisey as London saw out the victory.
New York claim maiden Lory Meagher Cup
In the Lory Meagher Cup, three first half goals proved decisive as New York beat 4-14 to 2-17 to win the competition for the first time.
Advertisement
New York were playing at Croke Park for the first time since 2006 after returning to the fifth tier of the hurling championship last weekend.
Cavan, meanwhile, were back in the final for the first time since losing the decider against Fermanagh in 2021 but struggled and they trailed 3-11 to 0-13 at half-time against a ruthless New York side.
Tomas O'Connor, AJ Willis and Dara Walsh all found the net whilst Adam Loughlin Stones and David Mangan racked up eight points between them to give the Exiles a comfortable lead at the break.
Mangan scored their fourth goal after the break from the penalty spot and they continued to keep the scoreboard ticking over, leading 4-14 to 0-15 at one stage in the second half.
Advertisement
Cavan rallied and netted two goals in the last quarter of the game to threaten a comeback.
Nicky Kenny pulled one back before Liam O'Brien scored a penalty for their second, but New York held on for the historic victory.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Drug maker Indivior joins the flight from London share listings
Drug maker Indivior has become the latest major UK listed company to scrap its London share trading. The pharmaceuticals company, which has its UK headquarters in Slough, said it planned to cancel its secondary listing in London. Indivior only moved its primary listing to Nasdaq last June and now wants to sever all share trading links with the City. The move comes just a year after Invidior's board said it planned to keep the London listing "for as long as it is considered to be in the best interests of Indivior and its shareholders as a whole." Reasons given for scrapping the London listing following a review include the fact that 80% of the company's revenue is generated in America; trading on Nasdaq accounts for approximately 75% of total volumes across both exchanges; more than 70% of the share are now held by investors located in the U.S; and the elimination of 'the cost and complexity of maintaining a secondary listing.' Another major factor is that the company's biggest selling drug Sublocade, a treatment for helping opioid addicts reduce their dependence, has its biggest market in the US. Last year Sublocade accounted for $756 million of the company's total $1.2 billion sales. Indivior was spun out of its former parent company, the consumer products giant Reckitt Benckizer in 2014 as a free standing London listed company. The Virginia based company's chair David Wheadon, said:"We are pleased to announce this key milestone for Indivior following our evaluation period. A single primary listing on Nasdaq best reflects the profile of Indivior's business. 'We appreciate the support received from shareholders for this initiative and look forward to capitalizing on the expected benefits of this move, including reductions in cost and complexity." London has suffered a major outflow of listed companies over recent years in a blow to the prestige of the City. A total of 88 firms delisted or transferred their primary listing from the London Stock Exchange last year, the highest number since the financial crisis of 2008, according to auditor EY. Only 18 companies came on to the London market last year as the vital flow of small and growing businesses raising capital by listing their shares on the London stock market dried up. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Returns On Capital Are Showing Encouraging Signs At Severfield (LON:SFR)
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. With that in mind, we've noticed some promising trends at Severfield (LON:SFR) so let's look a bit deeper. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. Analysts use this formula to calculate it for Severfield: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.12 = UK£32m ÷ (UK£388m - UK£133m) (Based on the trailing twelve months to September 2024). Therefore, Severfield has an ROCE of 12%. In absolute terms, that's a pretty standard return but compared to the Construction industry average it falls behind. See our latest analysis for Severfield In the above chart we have measured Severfield's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Severfield . The trends we've noticed at Severfield are quite reassuring. The data shows that returns on capital have increased substantially over the last five years to 12%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 25%. This can indicate that there's plenty of opportunities to invest capital internally and at ever higher rates, a combination that's common among multi-baggers. On a side note, we noticed that the improvement in ROCE appears to be partly fueled by an increase in current liabilities. The current liabilities has increased to 34% of total assets, so the business is now more funded by the likes of its suppliers or short-term creditors. It's worth keeping an eye on this because as the percentage of current liabilities to total assets increases, some aspects of risk also increase. In summary, it's great to see that Severfield can compound returns by consistently reinvesting capital at increasing rates of return, because these are some of the key ingredients of those highly sought after multi-baggers. Astute investors may have an opportunity here because the stock has declined 34% in the last five years. With that in mind, we believe the promising trends warrant this stock for further investigation. One final note, you should learn about the 4 warning signs we've spotted with Severfield (including 2 which shouldn't be ignored) . While Severfield may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
27 minutes ago
- Yahoo
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business. The company, known for its opioid addiction treatment, joins a growing number of companies delisting from London, as lower valuations and weak investor appetite continue to drive firms toward U.S. markets. Shares of Indivior, which floated in London in late 2014, have dropped more than 60% from record highs hit in June 2018. The company said over 80% of its revenue now comes from the U.S., with the Nasdaq accounting for about 75% of recent trading volumes. The delisting aims to streamline operations and reflect the company's strategic focus on the U.S. market, it said. Indivior moved its primary listing to the United States last year. The decision to delist from London comes just months after Indivior overhauled its management. Earlier this year, it appointed David Wheadon as chair and Joe Ciaffoni as CEO. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
